A Japanese panel voted to move 2 iPS cell therapies forward for approval despite there being minimal clinical trial data. Let’s discuss the context and potential risks.
Japan panel OK’s 2 iPS cell therapies despite little data Read More »
When I first read in 2019 that George Church previously had ties to Jeffrey Epstein, I felt disappointed. It’s been fun following Church’s research over the years. I even interviewed him here on The Niche about human germline CRISPR. Now, unfortunately, there are new revelations about Church’s Personal Genome Project (PGP) in the recent Epstein
Induced pluripotent stem cells or iPS cells just might be the most exciting development in the stem cell field over the last 19 years. They have unique potential for clinical impact for regenerative medicine too. This may manifest both through their use to produce differentiated cellular therapies and indirectly via disease modeling as well as
What are induced pluripotent stem cells or iPS cells? Read More »
IPS cell research is a growing area of promise for regenerative medicine. These stem cells, also known as iPSCs or more formally as Induced Pluripotent Stem Cells, are engineered cells that are programmed to function the same way as embryonic stem cells. They can be differentiated into possibly any type of cell that is needed for
Overview of IPS cell prospects for clinical impact Read More »
There’s never enough time to get all of one’s science reading done, but we can try! It helps to have a list of “to-read” articles, whether actual research articles or media pieces. In the old days, I remember my mentors saying they literally had “piles” of journal articles on their coffee tables, bathrooms, bedrooms, etc.
Weekly recommended science reads: stem cells, CRISPR, cancer & more Read More »
Where do things stand today in 2020 with IPS cell research? It’s been 14 years since they were first reported, but they continue to make news. Back in 2006 I was wrapping up my postdoc with Bob Eisenman at The Hutch in Seattle, largely studying Myc, when Shinya Yamanaka published his first induced pluripotent stem
IPS cell field update: easy culture, Parkinson’s, scarring, immune cells, & mutations Read More »
Masayo Takahashi is a leading stem cell researcher doing translational and clinical research on vision. She’s doing pioneering work on using pluripotent stem cells as a basis for helping patients with vision loss such as due to macular degeneration. She won The Niche’s Stem Cell Person of the Year Award in 2014 and a number
Masayo Takahashi (高橋 政代): exciting vision work advancing including with photoreceptors Read More »
The NIH announced the launch of the 1st autologous induced pluripotent stem (IPS) cell trial for vision loss in the U.S., focused on macular degeneration. The protocol is based on a solid foundation of pre-clinical animal studies: “Researchers at the National Eye Institute (NEI) are launching a clinical trial to test the safety of a
1st autologous IPS cell clinical trial for vision loss in the US Read More »
Here we go again with people trying to ban funding of embryonic stem cell research. Really? Yes, including according to a new article from the Catholic News Agency. Who is trying to get this ban? Some Republicans in The U.S. Senate. I’ve wondered for years if the Trump Administration might take action against embryonic stem
US Senate bill would ban embryonic stem cell research Read More »
In Parkinson’s Disease patients develop neurological dysfunction as they lose a special kind of brain cell called dopaminergic (or dopamine) neurons. While a number of different approaches to this disease have been studied for decades, nothing has proven particularly successful in slowing its progression. As a result there has been a big need for novel thinking
Hope on Parkinson’s front: Japan IPSC trial 1st patient Read More »